Lightnews — Scholar-powered news

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · 15d

We are thrilled to announce that we have generously received funding for a one-year hypertension fellowship, and we are recruiting now for a candidate to start fellowship July 1, 2026 .
med.stanford.edu/hypertension/e…

-Jehan Zahid Bahrainwala
HTN Fellowship Program Director

https://med.stanford.edu/hypertension/e…

6 10

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · 15d

x.com/stanford_htn...

x.com

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · 28d

Great reference

Reposted by Vivek Bhalla, MD, FASN, FAHA

grahamabra.bsky.social @grahamabra.bsky.social · Sep 5

A famous nephrologist getting ready to go see the most famous guy who plays a nephrologist @glaucomflecken.bsky.social @stanforddeptmed.bsky.social Grand Rounds!

1 4 12

Reposted by Vivek Bhalla, MD, FASN, FAHA

Adina Turcu @adinaturcu.bsky.social · Aug 28

#ENDO2026 Welcomes Your Ideas | Our annual meeting will take place in Chicago, IL, June 13–16, and I’m inviting YOU to shape the program💡Submit your symposium proposal or session suggestion by Tuesday, September 2: bit.ly/4flCMjl
#endocrinology @TheEndoSociety

ENDO 2026 Session Submissions

ENDO wouldn’t be possible without the insight and expertise of the Endocrine community. Your ideas are essential to building a dynamic, forward-thinking program that reflects the full breadth of our f...

bit.ly

5 5

Reposted by Vivek Bhalla, MD, FASN, FAHA

David Ho @davidho.bsky.social · Jul 30

Motherfucking wind farms…

1.2K 18K 47K

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Jul 24

Dr. Alessia Fornoni @alessiafornoni.bsky.social University of Miami describing her journey as a physician scientist, mentor, and drug developer- from a small town in northern Italy to her many roles today

3

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Jul 24

Drs. Prabir Roy-Chaudry @asnkidney.bsky.social president of the ASN, @uncchapelhill.bsky.social as well as Drs. Rasheed Gbadegesin @dukepress.bsky.social and Emmanuel Opara @wakeforest.bsky.social kicking off the KUH R25 symposium @dknet.org at UNC chapel hill today

1 2

Reposted by Vivek Bhalla, MD, FASN, FAHA

Science Magazine @science.org · Jul 8

“There is a lot of pressure to essentially leave the country or not pursue research.” scim.ag/3Gz4VWW

‘It’s a nightmare.’ U.S. funding cuts threaten academic science jobs at all levels

“There is a lot of pressure to essentially leave the country or not pursue research,” one Ph.D. student says

scim.ag

5 33 90

Reposted by Vivek Bhalla, MD, FASN, FAHA

NEJM.org @nejm.org · Jun 21

Presented at the #ADASciSessions:

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. This phase 1–2 study supports the hypothesis that zimislecel can restore physiologic islet function and thus treat persons with type 1 diabetes. Full study results: nej.md/3ZGupbv

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimisle...

nej.md

1 11 36

Reposted by Vivek Bhalla, MD, FASN, FAHA

Stanford Department of Medicine @stanforddeptmed.bsky.social · Jun 16

Congratulations to the #StanDOM recipients of the 2025 Stanford Medicine Awards, who were recognized for their outstanding contributions to medical education & leadership during the June 14 @stanfordmedicine.bsky.social graduation.

1 3

Reposted by Vivek Bhalla, MD, FASN, FAHA

euanashley @euanashley.bsky.social · Jun 14

Atul Butte died yesterday.
The world lost a giant.
A big bear of a man.
With a huge smile.
With love for everyone.
With energy that could power a room.
I loved everything about Atul.
I loved how he was always happy.
I loved how excited he was about science and helping people.

14 57 190

Reposted by Vivek Bhalla, MD, FASN, FAHA

Raider @iwillnotbesilenced.bsky.social · Jun 8

I don't care if these monstrous ICE raids are a "federal operation". This is authoritarian violence, plain and simple.

210 3.3K 14K

Reposted by Vivek Bhalla, MD, FASN, FAHA

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Jun 3

Congrats to all the @asnkidney.bsky.social lifetime and mid-career awardees!

@ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!

4 7 31

Reposted by Vivek Bhalla, MD, FASN, FAHA

Prof Liz Lightstone @kidneydoc101.bsky.social · May 23

Congratulations to all who advocated and thank you to all those who supported!!
🎉🎉🎉🎉🎉
@WHO.int
@ISN.org
#Guatamala

@CharuMalik.bsky.social
Ifeoma Ulasi
Magda Machalska

@UKKidney.org
@kidneycareuk.org
@KidneyResearch.org

#kidneyhealthforall
#WHA78

ISNkidneycare @theisn.org · May 23

🌍 History made! For the first time, kidney care is on the global health agenda. #WHA78 adopted a landmark resolution recognizing kidney health in the fight against #NCDs.

👏 Thanks to Guatemala and the global kidney community for making this possible!

#KidneyHealthMatters

2 9

Reposted by Vivek Bhalla, MD, FASN, FAHA

Stefan Marciniak @profmarciniak.bsky.social · May 4

The Dutch are responsible for many wonderful things, but are any as great as the stroopwafel and coffee combo? 🇳🇱☕️🧇

Zosia is very jealous

1 1 38

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Apr 24

Wanpen- interesting …do you have a reference? I believe baxdrostat is via CYP3A4? (Ie similar to eplerenone and tacrolimus, and therefore concerns with things like diltiazem and paxlovid)

1 1

Reposted by Vivek Bhalla, MD, FASN, FAHA

NEJM.org @nejm.org · Apr 23

In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf

#MedSky #CardioSky

A graph showing the least-squares mean changes from baseline (randomization) in the 24-hour average ambulatory systolic blood pressure at 12 weeks.

1 9 14

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Apr 24

Amen!

Reposted by Vivek Bhalla, MD, FASN, FAHA

Nature @nature.com · Apr 22

Kidney disease should be recognised on WHO's priority list of non-communicable diseases, alongside cancer, cardiovascular disease, and diabetes

https://go.nature.com/4lLJ5iY

Kidney disease is a worldwide killer. Treat it that way

The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of chronic kidney disease.

go.nature.com

2 21 58

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Apr 24

but this could change soon with ARCTIC, PACIFIC trials

Full disclosure: SABs for AZ, Bayer

1 4

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Apr 24

aldosterone sensitivity, etc.

Regarding ASIs vs MRAs, I was a big believer in eplerenone with its fewer side effects but have accumulated more and more folks where it’s simply not potent enough. This creates a lane for ASIs. nsMRAs (possibly MRAs in general) still have the upper hand for GDMT 2/n

1 1 6

Vivek Bhalla, MD, FASN, FAHA @bhallaresearch.bsky.social · Apr 24

Very exciting news…..success with this broad cohort continues a slow and steady march for blockade of aldosterone signaling as a major tool in hypertension more broadly (not just obvious cases of PA) by likely capturing common cases of subclinical PA, aldosterone dysregulation, 1/n

1 1 6

Reposted by Vivek Bhalla, MD, FASN, FAHA

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · Apr 23

The ASIs have arrived

www.nejm.org/doi/full/10....

Aldosterone synthase inhibitors - first one to finish the phase 3 line

#Lorundrostat #Hypertension

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM

Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...

www.nejm.org

3 27 37

Reposted by Vivek Bhalla, MD, FASN, FAHA

Jordy Cohen @jordybc.bsky.social · Apr 23

Aaand it’s official, we have a new antihypertensive class!!!! 🎉🍾🎊

I like this RCT design in particular because it was open to both uncontrolled not-yet-resistant AND resistant hypertensive patients, opening to door to prescribe it as an earlier line agent

www.nejm.org/doi/full/10....

Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM

Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...

www.nejm.org

4 15 46